Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SYRE Stock Forecast 2026-2027
$73.65
Current Price
$6.40B
Market Cap
Buy 17
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to SYRE Price Targets
+56.1%
To High Target of $115.00
+29.0%
To Median Target of $95.00
+5.9%
To Low Target of $78.00
SYRE Price Momentum
+0.2%
1 Week Change
+0.8%
1 Month Change
+334.0%
1 Year Change
+124.8%
Year-to-Date Change
-7.4%
From 52W High of $79.54
+428.7%
From 52W Low of $13.93
📊 TOP ANALYST CALLS
Did SYRE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Spyre Therapeutics is one of their latest high-conviction picks.
Latest SYRE Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, SYRE has a bullish consensus with a median price target of $95.00 (ranging from $78.00 to $115.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $73.65, the median forecast implies a 29.0% upside. This outlook is supported by 17 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from David Hoang at Deutsche Bank, projecting a 56.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SYRE Analyst Ratings
17
Buy
0
Hold
0
Sell
SYRE Price Target Range
Low
$78.00
Average
$95.00
High
$115.00
Current: $73.65
Latest SYRE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SYRE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 4, 2026 | Deutsche Bank | David Hoang | Buy | Maintains | $115.00 |
| May 6, 2026 | Citigroup | Samantha Semenkow | Buy | Maintains | $97.00 |
| May 6, 2026 | Stifel | Alex Thompson | Buy | Maintains | $107.00 |
| Apr 17, 2026 | Jones Trading | Buy | Maintains | $N/A | |
| Apr 14, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| Apr 14, 2026 | Wedbush | Outperform | Maintains | $N/A | |
| Apr 14, 2026 | Baird | Outperform | Maintains | $N/A | |
| Apr 14, 2026 | Raymond James | Strong Buy | Initiates | $N/A | |
| Apr 14, 2026 | Deutsche Bank | Buy | Maintains | $N/A | |
| Apr 13, 2026 | Leerink Partners | Outperform | Maintains | $N/A | |
| Apr 13, 2026 | Jefferies | Buy | Maintains | $N/A | |
| Apr 13, 2026 | BTIG | Buy | Maintains | $N/A | |
| Mar 31, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Mar 18, 2026 | Stifel | Buy | Maintains | $N/A | |
| Mar 16, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Feb 20, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| Feb 20, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Jan 16, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Dec 18, 2025 | Mizuho | Outperform | Initiates | $N/A | |
| Dec 17, 2025 | Citigroup | Buy | Initiates | $N/A |
Spyre Therapeutics, Inc. (SYRE) Competitors
The following stocks are similar to Spyre Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Spyre Therapeutics, Inc. (SYRE) Financial Data
Spyre Therapeutics, Inc. has a market capitalization of $6.40B with a P/E ratio of 1.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -31.1%.
Valuation Metrics
Market Cap
$6.40B
Enterprise Value
$5.81B
P/E Ratio
1.7x
PEG Ratio
0.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+11.6%
Current Ratio
9.0x
Debt/Equity
0.0x
ROE
-31.1%
ROA
-22.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Spyre Therapeutics, Inc. (SYRE) Business Model
About Spyre Therapeutics, Inc.
What They Do
Develops next-generation antibodies for immune diseases.
Business Model
The company operates as a clinical-stage biotechnology firm, generating revenue through the development and commercialization of innovative antibody therapies targeting inflammatory bowel disease and other immune-mediated conditions. Its business model involves conducting clinical trials to validate the efficacy of its products, which may eventually lead to market approval and sales.
Additional Information
Founded in 2013 and based in Waltham, Massachusetts, Spyre Therapeutics aims to provide significant improvements in treatment efficacy and convenience for patients suffering from high-burden immune-mediated disorders. The company's pipeline includes promising candidates like SPY001, currently undergoing clinical evaluation.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
65
CEO
Dr. Cameron Turtle DPHIL, Ph.D.
Country
United States
IPO Year
2016
Website
www.spyre.comSpyre Therapeutics, Inc. (SYRE) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
SYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock Up
Spyre Therapeutics gains after completing enrollment in all SKYWAY phase II sub-studies evaluating SPY072 across three rheumatic diseases.
Jun 04, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Spyre Therapeutics granted 51,300 stock options to four non-executive employees as inducement awards, approved on June 1, 2026, under its 2018 Equity Inducement Plan.
Why It Matters
The stock options grant signals management's commitment to attracting talent, potentially enhancing innovation and growth, which can positively impact Spyre's stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Enrollment for the psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of the SKYWAY basket trial has been completed.
Why It Matters
Completion of enrollment in these sub-studies indicates progress in drug development, potentially leading to new treatments and impacting stock valuations for related biotech companies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Spyre Therapeutics' stock rises after finishing enrollment for all SKYWAY phase II sub-studies assessing SPY072 in three rheumatic diseases.
Why It Matters
Spyre Therapeutics' successful enrollment in SKYWAY phase II sub-studies boosts confidence in SPY072's potential, signaling progress and possibly enhancing future revenue prospects in rheumatic diseases.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Spyre Therapeutics, Inc. (NASDAQ: SYRE) will participate in upcoming investor conferences, focusing on long-acting antibodies for inflammatory bowel and rheumatic diseases.
Why It Matters
Spyre Therapeutics' participation in investor conferences can enhance visibility, attract potential investors, and signal confidence in its pipeline for treating IBD and rheumatic diseases.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
1 month ago
Quick Summary
Spyre Therapeutics announced positive Phase 2 SKYLINE trial data for SPY001, increased enrollment in the SKYWAY trial, and raised $463 million, with $1.2 billion in cash as of March 31, 2026.
Why It Matters
Positive trial results and upcoming readouts boost confidence in Spyre's pipeline, while strong cash reserves ensure financial stability through 2029, enhancing growth potential.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Spyre Therapeutics' stock increased by 73% in a month following positive mid-stage data for SPY001, indicating strong efficacy and safety in treating ulcerative colitis.
Why It Matters
Spyre Therapeutics' stock surge reflects increased investor confidence in SPY001's potential, possibly leading to higher valuations and interest from institutional investors.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About SYRE Stock
What is Spyre Therapeutics, Inc.'s (SYRE) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Spyre Therapeutics, Inc. (SYRE) has a median price target of $95.00. The highest price target is $115.00 and the lowest is $78.00.
Is SYRE stock a good investment in 2026?
According to current analyst ratings, SYRE has 17 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $73.65. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SYRE stock?
Wall Street analysts predict SYRE stock could reach $95.00 in the next 12 months. This represents a 29.0% increase from the current price of $73.65. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Spyre Therapeutics, Inc.'s business model?
The company operates as a clinical-stage biotechnology firm, generating revenue through the development and commercialization of innovative antibody therapies targeting inflammatory bowel disease and other immune-mediated conditions. Its business model involves conducting clinical trials to validate the efficacy of its products, which may eventually lead to market approval and sales.
What is the highest forecasted price for SYRE Spyre Therapeutics, Inc.?
The highest price target for SYRE is $115.00 from David Hoang at Deutsche Bank, which represents a 56.1% increase from the current price of $73.65.
What is the lowest forecasted price for SYRE Spyre Therapeutics, Inc.?
The lowest price target for SYRE is $78.00 from at , which represents a 5.9% increase from the current price of $73.65.
What is the overall SYRE consensus from analysts for Spyre Therapeutics, Inc.?
The overall analyst consensus for SYRE is bullish. Out of 4 Wall Street analysts, 17 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $95.00.
How accurate are SYRE stock price projections?
Stock price projections, including those for Spyre Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 7, 2026 6:57 PM UTC